World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
95
Citations
46854
World Ranking
9891
National Ranking
5090

Robert I. Haddad publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Robert I. Haddad sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 454 publications — 50th percentile

50% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Robert I. Haddad D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Robert I. Haddad sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 95 D-Index — 51st percentile

51% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Robert I. Haddad is affiliated with Harvard University in the United States, with a research focus largely centered in the field of Medicine. Their scholarly output is predominantly grounded in Oncology, with significant contributions to related subfields such as Otorhinolaryngology, Pulmonary and Respiratory Medicine, Surgery, and Molecular Biology.

Their primary research topics explore areas including:

  • Head and Neck Cancer Studies
  • Cancer Immunotherapy and Biomarkers
  • Lung Cancer Treatments and Mutations
  • Colorectal and Anal Carcinomas
  • Cancer Genomics and Diagnostics
  • Cancer Diagnosis and Treatment
  • Lung Cancer Research Studies

Among recent notable papers associated with their area of study are:

  • "Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology" (2020), published in the Journal of the National Comprehensive Cancer Network
  • "Head and neck cancer" (2021), published in The Lancet
  • "Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial" (2021), published in The Lancet Oncology
  • "NCCN Guidelines® Insights: Head and Neck Cancers, Version 1.2022" (2022), published in the Journal of the National Comprehensive Cancer Network
  • "Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology" (2022), published in the Journal of the National Comprehensive Cancer Network

Robert I. Haddad frequently collaborates with several researchers, including:

  • Glenn J. Hanna
  • Jonathan D. Schoenfeld
  • Ravindra Uppaluri
  • Roy B. Tishler
  • Kartik Sehgal

Their publications are often featured in major journals with repeated contributions, such as:

  • Journal of Clinical Oncology
  • International Journal of Radiation Oncology*Biology*Physics
  • Clinical Cancer Research
  • Cancer Research
  • Annals of Oncology

Best Publications

  • Comprehensive genomic characterization of head and neck squamous cell carcinomas

    Michael S. Lawrence;Carrie Sougnez;Lee Lichtenstein;Kristian Cibulskis

  • Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

    Robert L. Ferris;George Blumenschein;Jerome Fayette;Joel Guigay

  • Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.

    Marshall R. Posner;Diane M. Hershock;Cesar R. Blajman;Elizabeth Mickiewicz

  • Recent Advances in Head and Neck Cancer

    Robert I. Haddad;Dong M. Shin

  • Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort

    Laura Q.M. Chow;Robert Haddad;Shilpa Gupta;Amit Mahipal

  • Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.

    David G. Pfister;Sharon Spencer;David Adelstein;Douglas Adkins

  • Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.

    Robert Haddad;Robert Haddad;Anne O'Neill;Guilherme Rabinowits;Roy Tishler

  • Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.

    Robert L. Ferris;George Blumenschein;Jerome Fayette;Joel Guigay

  • Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study.

    Joshua Bauml;Tanguy Y. Seiwert;David G. Pfister;Francis Worden

  • Head and Neck Cancers, Version 2.2014

    David G. Pfister;Sharon Spencer;David M. Brizel;Barbara Burtness

  • Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial

    M. R. Posner;J. H. Lorch;O. Goloubeva;M. Tan

  • NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018

    A. Dimitrios Colevas;Sue S. Yom;David G. Pfister;Sharon Spencer

  • Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.

    Jochen H Lorch;Olga Goloubeva;Robert I Haddad;Kevin Cullen

  • Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors

    Diana Miao;Diana Miao;Claire A. Margolis;Claire A. Margolis;Natalie I. Vokes;Natalie I. Vokes;David Liu;David Liu

  • Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial

    Jean Pascal H Machiels;Robert I. Haddad;Jérôme Fayette;Lisa F. Licitra

  • Characterization of HPV and host genome interactions in primary head and neck cancers.

    Michael Parfenov;Chandra Sekhar Pedamallu;Nils Gehlenborg;Nils Gehlenborg;Samuel S. Freeman

  • Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial

    Kevin J Harrington;Robert L Ferris;George Blumenschein;A Dimitrios Colevas

  • Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.

    Nancy Y Lee;Robert L Ferris;Amanda Psyrri;Robert I Haddad

  • Head and Neck Cancers

    David G. Pfister;Kie Kian Ang;David M. Brizel;Barbara A. Burtness

  • Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012.

    Ranee Mehra;Ranee Mehra;Tanguy Y. Seiwert;Shilpa Gupta;Shilpa Gupta;Jared Weiss

Frequent Co-Authors

Marshall R. Posner
Marshall R. Posner Icahn School of Medicine at Mount Sinai
Lisa Licitra
Lisa Licitra University of Milan
Robert L. Ferris
Robert L. Ferris University of Pittsburgh
Kevin J. Harrington
Kevin J. Harrington Royal Marsden NHS Foundation Trust
Ezra E.W. Cohen
Ezra E.W. Cohen University of California, San Diego
Maura L. Gillison
Maura L. Gillison The University of Texas MD Anderson Cancer Center
George R. Blumenschein
George R. Blumenschein The University of Texas MD Anderson Cancer Center
Everett E. Vokes
Everett E. Vokes University of Chicago
Jatin P. Shah
Jatin P. Shah Memorial Sloan Kettering Cancer Center
Paul J. Catalano
Paul J. Catalano Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those exploring alternatives to studying Medicine in the USA, there are several rewarding healthcare career paths that can be pursued online. Many students are drawn to fields like financial aid for medical billing and coding, which offer flexible learning options and opportunities for financial assistance, making it accessible to a wide range of learners.

Nursing remains a popular choice, and it's important to note that do all nursing schools require the teas is a common question. Some top nursing schools no longer require TEAS or HESI exams, streamlining the admissions process for aspiring nurses.

If you are interested in leadership in healthcare, consider pursuing an online healthcare management degree. Accelerated programs are available, providing pathways to move quickly into administrative and managerial roles in various healthcare settings.

Registered nurses looking to advance their careers can explore rn to fnp programs, which are designed to bridge the gap from ADN to MSN and open doors to becoming a Family Nurse Practitioner.

Best Scientists Citing Robert I. Haddad

Trending Scientists

Recently Published Articles